Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironmentOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tracked how gut bacteria shift as the colon progresses from healthy tissue to adenoma to cancer. It then tested whether Fusobacterium nucleatum drives tumors and whether the plant compound berberine can reverse the damage. Researchers combined human 16S pyrosequencing with mouse experiments using bacterial feeding, a chemical carcinogen, and cytokine and protein assays.
Who was studied?
The human samples came from 52 healthy controls, 47 adenoma patients, and 42 colorectal cancer patients, all over age 50, plus colonic tissue from 98 people. The mouse work used 50 APC-Min mice and 90 wild-type C57BL/6 mice. Mice were fed Fusobacterium nucleatum or control Escherichia coli, injected with the carcinogen dimethylhydrazine, and treated with berberine by gavage.
What were the most important findings?
Opportunistic pathogens rose steadily along the adenoma-carcinoma sequence. Enterococcus climbed from 0.26 to 1.42 to 2.75 percent (P=0.004), and Fusobacterium from 0.26 to 0.61 to 1.22 percent (P=0.031), with Streptococcus also increasing. Beneficial genera including Roseburia, Clostridium and Bifidobacterium fell across the same sequence. Fusobacterium nucleatum feeding increased colon tumors in mice and disturbed their microbiota. Berberine reversed the Fusobacterium-induced imbalance and reduced tumors. It lowered cytokines IL-21/22/31 and CD40L and blocked activation of the JAK/STAT and MAPK/ERK pathways.
What are the greatest implications of this study?
The results position Fusobacterium nucleatum as an active promoter of colorectal tumors, not just a bystander, acting through the tumor-immune microenvironment. Rising Enterococcus and Streptococcus mark the shift toward cancer. Berberine, a long-used herbal compound, could rescue this process by rebalancing bacteria and blocking tumor-promoting signaling. This supports exploring berberine and microbiota-targeted strategies for colorectal cancer prevention.